Head-To-Head Contrast: Mirati Therapeutics (MRTX) versus Its Peers
Mirati Therapeutics (NASDAQ: MRTX) is one of 93 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Mirati Therapeutics to similar businesses based on the strength of its dividends, valuation, risk, profitability, earnings, analyst recommendations and institutional ownership.
This is a breakdown of recent ratings and price targets for Mirati Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mirati Therapeutics Competitors||163||543||1199||16||2.56|
Mirati Therapeutics currently has a consensus target price of $9.00, suggesting a potential upside of 87.50%. As a group, “Biotechnology” companies have a potential upside of 58.88%. Given Mirati Therapeutics’ higher probable upside, equities research analysts clearly believe Mirati Therapeutics is more favorable than its rivals.
Earnings and Valuation
This table compares Mirati Therapeutics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Mirati Therapeutics||N/A||-$73.47 million||-1.40|
|Mirati Therapeutics Competitors||$223.74 million||$57.84 million||-0.65|
Mirati Therapeutics’ rivals have higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Mirati Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Mirati Therapeutics’ rivals have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.
Insider & Institutional Ownership
60.2% of Mirati Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 5.1% of Mirati Therapeutics shares are owned by company insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Mirati Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mirati Therapeutics Competitors||-917.30%||-187.05%||-24.43%|
Mirati Therapeutics rivals beat Mirati Therapeutics on 7 of the 12 factors compared.
About Mirati Therapeutics
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.